Literature DB >> 11062357

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

G Y Boivin1, P M Chavassieux, A C Santora, J Yates, P J Meunier.   

Abstract

The mean degree of mineralization of bone (MDMB) was measured by quantitative microradiography on transiliac bone biopsies taken from 53 postmenopausal osteoporotic women who had been treated with alendronate (ALN; 10 mg/day) during 2 (9 patients) or 3 years (16 patients) or with placebo (PLA; 15 and 13 patients, respectively). In the same patients, bone mineral density (BMD) values were obtained by dual-energy X-ray absorptiometry of the lumbar spine and femoral neck at the beginning and end of treatment. Histomorphometric parameters and activation frequency of new remodeling units were also measured on the iliac biopsies. After 2 years of ALN, MDMB in compact bone was 9.3% (p = 0.0035) and in cancellous bone was 7.3% (p = 0.0009) higher, respectively, than PLA. After 3 years of ALN, MDMB in compact bone was 11.6% (p = 0.0002) and in cancellous bone was 11.4% (p = 0.0001) higher, respectively, than PLA. After 2 and 3 years of ALN, and compared with the corresponding PLA, the distribution of the degree of mineralization in compact and cancellous bone showed a clear shift toward the highest mineralization values and a decrease in the number of bone structure units having low values of mineralization. The between-group differences in MDMB were similar to those of BMD at the lumbar spine BMD (+8.7% after 2 years and +9.6% after 3 years, respectively), suggesting that MDMB augmentation probably accounted for the majority of the increase in BMD seen with ALN. The data support the hypothesis that the reduction in activation frequency caused by the antiresorptive effect of ALN is followed by a prolonged secondary mineralization that increases the percentage of bone structure units having reached a maximum degree of secondary mineralization and, through this mechanism, MDMB. That these effects contribute to improved bone strength is demonstrated by the reduction in fracture incidence previously demonstrated in these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062357     DOI: 10.1016/s8756-3282(00)00376-8

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  136 in total

Review 1.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

2.  Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment.

Authors:  Masataka Shiraki; Tatsuhiko Kuroda; Yumiko Shiraki; Shiro Tanaka; Tsuyoshi Higuchi; Mitsuru Saito
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

3.  Changes in proximal femur bone properties following ovariectomy and their association with resistance to fracture.

Authors:  Hélder Fonseca; Daniel Moreira-Gonçalves; Mário Vaz; Maria Helena Fernandes; Rita Ferreira; Francisco Amado; Maria Paula Mota; José Alberto Duarte
Journal:  J Bone Miner Metab       Date:  2011-09-21       Impact factor: 2.626

Review 4.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

5.  Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.

Authors:  R D Chapurlat; M Laroche; T Thomas; S Rouanet; P D Delmas; M-C de Vernejoul
Journal:  Osteoporos Int       Date:  2012-03-09       Impact factor: 4.507

6.  Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.

Authors:  N Morabito; A Gaudio; A Lasco; C Vergara; F Tallarida; G Crisafulli; A Trifiletti; M Cincotta; M A Pizzoleo; N Frisina
Journal:  Osteoporos Int       Date:  2003-05-15       Impact factor: 4.507

Review 7.  Bone quality: where do we go from here?

Authors:  Mary L Bouxsein
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 8.  Methodological considerations in measurement of bone mineral content.

Authors:  Georges Boivin; Pierre J Meunier
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

9.  Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.

Authors:  M R Allen; D B Burr
Journal:  Osteoporos Int       Date:  2007-08-21       Impact factor: 4.507

Review 10.  Strontium ranelate: a novel mode of action leading to renewed bone quality.

Authors:  Patrick Ammann
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.